Literature DB >> 21531818

Dopamine blocks stress-mediated ovarian carcinoma growth.

Myrthala Moreno-Smith1, Chunhua Lu, Mian M K Shahzad, Guillermo N Armaiz Pena, Julie K Allen, Rebecca L Stone, Lingegowda S Mangala, Hee Dong Han, Hye Sun Kim, Donna Farley, Gabriel Lopez Berestein, Steve W Cole, Susan K Lutgendorf, Anil K Sood.   

Abstract

PURPOSE: Increased adrenergic activity in response to chronic stress is known to promote tumor growth by stimulating the tumor microenvironment. The focus of the current study was to determine whether dopamine, an inhibitory catecholamine, could block the effects of chronic stress on tumor growth. EXPERIMENTAL
DESIGN: Expression of dopamine receptors (DR1-DR5) was analyzed by reverse transcriptase-PCR and by Western blotting. In vitro effects of dopamine on cell viability, apoptosis, and migration were examined. For in vivo therapy, murine and human DR2-siRNAs were incorporated into chitosan nanoparticles (CH-NP).
RESULTS: In this model of chronic stress, tumoral norepinephrine levels remained elevated whereas dopamine levels were significantly decreased compared with nonstressed animals. Daily restraint stress resulted in significantly increased tumor growth in both immunodeficient (SKOV3ip1 and HeyA8) and immunocompetent (ID8) ovarian cancer models. This increase was completely blocked with daily dopamine treatment. Dopamine treatment also blocked the stress-induced increase in angiogenesis. Endothelial and ovarian cancer cells expressed all dopamine receptors except for the lack of DR3 expression in ovarian cancer cells. DR2 was responsible for the inhibitory effects of dopamine on tumor growth and microvessel density as well as the stimulatory effect on apoptosis, as the DR2 antagonist eticlopride reversed these effects. Dopamine significantly inhibited cell viability and stimulated apoptosis in vitro. Moreover, dopamine reduced cyclic AMP levels and inhibited norepinephrine and vascular permeability factor/VEGF-induced Src kinase activation.
CONCLUSIONS: Dopamine depletion under chronic stress conditions creates a permissive microenvironment for tumor growth that can be reversed by dopamine replacement. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21531818      PMCID: PMC3107884          DOI: 10.1158/1078-0432.CCR-10-2441

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  40 in total

Review 1.  Dopamine agonist therapy for hyperprolactinemia.

Authors:  Brandon J Bankowski; Howard A Zacur
Journal:  Clin Obstet Gynecol       Date:  2003-06       Impact factor: 2.190

Review 2.  Stress-induced immune dysfunction: implications for health.

Authors:  Ronald Glaser; Janice K Kiecolt-Glaser
Journal:  Nat Rev Immunol       Date:  2005-03       Impact factor: 53.106

3.  The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor.

Authors:  S Basu; J A Nagy; S Pal; E Vasile; I A Eckelhoefer; V S Bliss; E J Manseau; P S Dasgupta; H F Dvorak; D Mukhopadhyay
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

4.  The incidence of cancer in schizophrenic patients.

Authors:  P B Mortensen
Journal:  J Epidemiol Community Health       Date:  1989-03       Impact factor: 3.710

5.  Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.

Authors:  Liz Y Han; Charles N Landen; Jose G Trevino; Jyotsnabaran Halder; Yvonne G Lin; Aparna A Kamat; Tae-Jin Kim; William M Merritt; Robert L Coleman; David M Gershenson; William C Shakespeare; Yihan Wang; Raji Sundaramoorth; Chester A Metcalf; David C Dalgarno; Tomi K Sawyer; Gary E Gallick; Anil K Sood
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

6.  Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness.

Authors:  Douglas D Boyd; Heng Wang; Hector Avila; Nila U Parikh; Horst Kessler; Victor Magdolen; Gary E Gallick
Journal:  Clin Cancer Res       Date:  2004-02-15       Impact factor: 12.531

7.  Acute stress induces time-dependent responses in dopamine mesolimbic system.

Authors:  S Puglisi-Allegra; A Imperato; L Angelucci; S Cabib
Journal:  Brain Res       Date:  1991-07-19       Impact factor: 3.252

Review 8.  Role of dopamine in schizophrenia and Parkinson's disease.

Authors:  J Birtwistle; D Baldwin
Journal:  Br J Nurs       Date:  1998 Jul 23-Aug 12

9.  Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis.

Authors:  Robert R Langley; Karen M Ramirez; Rachel Z Tsan; Melissa Van Arsdall; Monique B Nilsson; Isaiah J Fidler
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

Review 10.  Role of dopamine in malignant tumor growth.

Authors:  S Basu; P S Dasgupta
Journal:  Endocrine       Date:  2000-06       Impact factor: 3.925

View more
  35 in total

Review 1.  Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma.

Authors:  Thamara E Osinga; Thera P Links; Robin P F Dullaart; Karel Pacak; Anouk N A van der Horst-Schrivers; Michiel N Kerstens; Ido P Kema
Journal:  FASEB J       Date:  2017-03-06       Impact factor: 5.191

Review 2.  Neuroendocrine influences on cancer progression.

Authors:  Guillermo N Armaiz-Pena; Steve W Cole; Susan K Lutgendorf; Anil K Sood
Journal:  Brain Behav Immun       Date:  2012-06-21       Impact factor: 7.217

3.  Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer.

Authors:  D C Borcherding; W Tong; E R Hugo; D F Barnard; S Fox; K LaSance; E Shaughnessy; N Ben-Jonathan
Journal:  Oncogene       Date:  2015-10-19       Impact factor: 9.867

Review 4.  Neural regulation of hematopoiesis, inflammation, and cancer.

Authors:  Maher Hanoun; Maria Maryanovich; Anna Arnal-Estapé; Paul S Frenette
Journal:  Neuron       Date:  2015-04-22       Impact factor: 17.173

Review 5.  Dopamine receptors - IUPHAR Review 13.

Authors:  Jean-Martin Beaulieu; Stefano Espinoza; Raul R Gainetdinov
Journal:  Br J Pharmacol       Date:  2015-01       Impact factor: 8.739

6.  Social influences on clinical outcomes of patients with ovarian cancer.

Authors:  Susan K Lutgendorf; Koen De Geest; David Bender; Amina Ahmed; Michael J Goodheart; Laila Dahmoush; M Bridget Zimmerman; Frank J Penedo; Joseph A Lucci; Parvin Ganjei-Azar; Premal H Thaker; Luis Mendez; David M Lubaroff; George M Slavich; Steven W Cole; Anil K Sood
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

7.  Mirtazapine inhibits tumor growth via immune response and serotonergic system.

Authors:  Chun-Kai Fang; Hong-Wen Chen; I-Tsang Chiang; Chia-Chieh Chen; Jyh-Fei Liao; Ton-Ping Su; Chieh-Yin Tung; Yosuke Uchitomi; Jeng-Jong Hwang
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

Review 8.  Role of the Nervous System in Tumor Angiogenesis.

Authors:  Nyanbol Kuol; Lily Stojanovska; Vasso Apostolopoulos; Kulmira Nurgali
Journal:  Cancer Microenviron       Date:  2018-03-04

9.  Moderate swimming suppressed the growth and metastasis of the transplanted liver cancer in mice model: with reference to nervous system.

Authors:  Q-B Zhang; B-H Zhang; K-Z Zhang; X-T Meng; Q-A Jia; Q-B Zhang; Y Bu; X-D Zhu; D-N Ma; B-G Ye; N Zhang; Z-G Ren; H-C Sun; Z-Y Tang
Journal:  Oncogene       Date:  2015-12-21       Impact factor: 9.867

Review 10.  Neurotransmitters as regulators of tumor angiogenesis and immunity: the role of catecholamines.

Authors:  Chandrani Sarkar; Debanjan Chakroborty; Sujit Basu
Journal:  J Neuroimmune Pharmacol       Date:  2012-08-11       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.